M&A Deal Summary |
|
|---|---|
| Date | 2020-01-13 |
| Target | Pfizer - CK 1 Business |
| Sector | Life Science |
| Buyer(s) | Biogen |
| Sellers(s) | Pfizer |
| Deal Type | Divestiture |
| Deal Value | 75M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1978 |
| Sector | Life Science |
| Employees | 7,570 |
| Revenue | 9.8B USD (2023) |
Biogen is a biopharmaceutical company focused on discovering, developing, and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen was founded in 1978 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 9 |
| Sector (Life Science) | 7 of 9 |
| Type (Divestiture) | 2 of 2 |
| State (New York) | 1 of 1 |
| Country (United States) | 4 of 6 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 8 of 8 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-03-12 |
Biogen - Biologics Manufacturing Site
Hillerød, Denmark Biogen (Denmark) Manufacturing ApS is a biologics manufacturing site. Hillerød site includes a 90,000L biologics production facility with assembly, labeling and packing capabilities, quality control laboratories and warehouses. |
Sell | $890M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-07-28 |
Reata
Plano, Texas, United States Reata engages in developing novel oral anti-inflammatory drugs targeting NrF2. This important biological target has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress. Reata was founded in 2002 and is based in Plano, Texas. |
Buy | $7.3B |
| Category | Company |
|---|---|
| Founded | 1849 |
| Sector | Life Science |
| Employees | 8,300 |
| Revenue | 58.5B USD (2023) |
Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 18 |
| Sector (Life Science) | 10 of 13 |
| Type (Divestiture) | 13 of 15 |
| State (New York) | 1 of 1 |
| Country (United States) | 11 of 13 |
| Year (2020) | 1 of 2 |
| Size (of disclosed) | 8 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-07-29 |
The Upjohn Company
Kalamazoo, Michigan, United States Upjohn seeks to leverage our portfolio, global experience and expertise to become the trusted partner of choice for all stakeholders committed to improving patient health. Upjohn focuses on relieving the burden of non-communicable diseases with trusted, quality medicines for every patient, everywhere. Upjohn brings together 20 of the industry's most trusted brands — products such as Lipitor, Norvasc, Lyrica and Viagra — with world-class medical, manufacturing and commercial expertise in more than 120 countries. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-04-22 |
FoRx Therapeutics
Basel, Switzerland FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways. FoRx Therapeutics was founded in 2019 and is based in Basel, Switzerland. |
Buy | - |
